Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ea030178701ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product
EX-99.1 2 ea030178701ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year Received ISO 13485 Certification Ahead of Schedule; International Expansion Planned StereoCED™ Drug Delivery System Expected to be Available for Research and Investigational Clinical Studies by the End of Fiscal Year 2026 Management to Host Conference Call at 8:30 a.m. Eastern Time Today EDEN PRAIRIE, Minn., August 13, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming t...
Source
Exhibit EX-99.1
0001213900-26-088719
Filed August 13, 2026 at 12:15 PM UTC. The figures above are from the audited statements, not from this release.